This study is currently recruiting patients.
Sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
This study will evaluate the safety and effectiveness of anakinra (Kineret[R]) for treating patients with neonatal onset multisystem inflammatory disease (NOMID), also known as chronic infantile neurological, cutaneous and arthropathy (CINCA) syndrome. This disease can cause rash, joint deformities, brain inflammation, eye problems, and learning difficulties. Immune suppressing medicines commonly used to treat NOMID do not completely get rid of the disease symptoms and, if used for a long time in high doses, can cause harmful side effects. Anakinra, approved by The Food and Drug Administration for treating rheumatoid arthritis in adults, blocks a substance called IL-1 that may be an important factor in causing the inflammation in NOMID.
Study ID Numbers: 030298; 03-AR-0298
NLM Identifier: NCT00069329
COPYRIGHT 2004 Journal of Drugs in Dermatology
COPYRIGHT 2004 Gale Group
Home
A
8-Hour Bayer
